BioSpace News Archive

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 131,000 shares of the company’s common stock to four new employees.

Connect Biopharma Holdings Limited announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis.

IQVIA Holdings Inc. will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 19,400 shares of TCR2’s common stock to 1 new non-executive employees.

Adamis Pharmaceuticals Corporation announced that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced its presentation at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Diego.

Johnson & Johnson will participate in the Credit Suisse 31st Annual Global Healthcare Conference on Thursday, November 10th, 2022 at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 12:50 p.m.

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that, on September 30, 2022, the Company entered into an Amendment No. 2 to Loan and Security Agreement with SLR Investment Corp., as Collateral Agent, and the lenders party thereto.

Rocket Pharmaceuticals, Inc., a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 44,300 shares of G1’s common stock and 29,400 restricted stock units to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.